Neuroprotective Glp 1 Receptor Interaction

Recent clinical studies have begun to explore the neuroprotective potential of GLP-1RAs in various neurological disorders, though results have been mixed, likely reflecting differences in study design, patient selection, and dosing regimens.

This study provides evidence that the effects of GLP-1 receptor agonists may extend beyond their known metabolic and cardioprotective benefits to include neuroprotection, associated with a decreased risk of developing various neurodegenerative disorders.

Preclinical data on GLP-1 and GLP-1 RAs have displayed an impressive neuroprotective efficacy in stroke, Parkinson's disease (PD), Alzheimer's disease (AD), Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.

GLP-1 receptor agonists (GLP-1RAs) exemplify MTMC agents, with pleiotropic anti-inflammatory effects that span pathways such as NF-B and Toll-like receptors.

ctivation of the GLP-1R mediates neuroprotective effects through multiple mechanisms, including reducing neuroinflammation and oxidative stress, modulating synaptic plasticity, improving cognitive function and inhibiting neuronal apoptosis.

Furthermore, visual representations like the one above help us fully grasp the concept of Neuroprotective Glp 1 Receptor Interaction.

GLP-1 receptor analogs protect synapses and drive synaptogenesis. Extensive synapse loss, already apparent during the mild cognitive impairment (MCI) preclinical stage, is one of the earliest pathologic alterations in AD (John and Reddy, 2021).

Methods: This review explores the potential of Glucagon-like Peptide-1 receptor agonists (GLP-1RA), commonly used for type 2 diabetes and obesity, in managing OSA.